GLP-1 agonist drug prescriptions surge 600% in U.S

CTV News May 25, 2024, 03:00 PM UTC

Summary: Prescriptions for GLP-1 agonist drugs in the U.S. for weight loss and diabetes among ages 12-25 surged 594.4% from 2020 to 2023, with young women and girls seeing the largest increase. The study, published in JAMA, analyzed data from over 93% of U.S. retail pharmacies. Obesity and type 2 diabetes are rising among young people, with predictions of a 673% increase in type 2 diabetes cases by 2060.

Full article

Article metrics
Significance5.1
Scale & Impact0.0
Positivity4.0
Credibility8.0

What is this?

This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.

My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.

Read more about how I calculate significance, or see today's top ranked news on the main page:

See today's news rankings

Timeline:

  1. [2.4]
    Youth use of weight-loss drugs, like Wegovy, surges (BusinessMirror)
    145d 10h
    Source
  2. [2.9]
    Weight-loss drug use rises among youth, young adults (Voice of America - VOA News)
    145d 21h
    Source
  3. [3.6]
    Prescriptions for weight loss, diabetes drugs surge among youth (CNN)
    147d 6h
    Source
  4. [2.7]
    Child Ozempic use up 600% in 3 years, safety questioned (New York Post )
    147d 10h
    Source
  5. [4.2]
    Four in 10 adults with diabetes use GLP-1 RA (The Cardiology Advisor)
    149d 15h
    Source
  6. [4.6]
    Survey finds weight loss drugs used beyond chronic conditions (Scripps News)
    150d 10h
    Source